Aurobindo Pharma’s stepdown subsidiary -- Eugia Steriles has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its new injectable facility situated at Parawada Mandal, Anakapalli District, Andhra Pradesh. The USFDA had conducted an inspection from March 28, 2024 to April 05, 2024 at this facility. The said inspection is closed.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
